Decision Makers
Chief Marketing Officer
They are responsible for the creation and implementation of marketing and advertising campaigns and for using ads to boost sales. E-mail: f****@yahoo.com, Phone: 13019904800 is available on SoftwareOfficial.
Senior Director, Clinical Development
Jeff Herpst is in charge of making important choices for Zyngenia, Inc. E-mail: j****@lycos.com, Phone: 13019904800 is available on SoftwareOfficial.
Associate Director
David LaFleur is in control of making strategically essential decisions for Zyngenia, Inc. E-mail: d****@yahoo.com, Phone: 13019904800 is available on SoftwareOfficial.
Indian Institute Of Technology
This professional is responsible for choosing strategically significant development path. E-mail: p****@aol.com, Phone: 13019904800 is available on SoftwareOfficial.
Company Details
Last Update
Jul 13, 2022
Location
21 Firstfield Rd SUITE 200, Gaithersburg, MD 20878
PO Box 3130, Gaithersburg, MD 20885
Phone
(***) ***-4800
Industry
Biotechnology
Commercial Physical Research
Category
Government Contractors
Research & Development Laboratories
Specialties
Single-Protein Combination Therapeutics
Founded
2009
Number of Employee
11-50 employees
NAICS
623 - Nursing and Residential Care Facilities
FAQs about decision-makers at Zyngenia, Inc
What is the probable location of the Zyngenia, Inc?
The company Zyngenia address is in Gaithersburg, Maryland state.
What are the industries connected with Zyngenia?
The industries connected with the company Zyngenia are Biotechnology and Commercial Physical Research.
What is the known phone number of Zyngenia?
The phone number of the company Zyngenia decision-makers is 13019904800.
What are the names of the key decision-makers in Zyngenia?
The decision-makers of this company are Jeff Herpst, Frank Hsu etc.
What are the professions of the main decision-makers in Zyngenia?
The specialties of the company decision-makers are Chief Marketing Officer or Senior Director, Clinical Development etc.
What are the fields for Zyngenia?
The specialties connected with Zyngenia are Single-Protein Combination Therapeutics